The Cochrane database of systematic reviews

Interventions for Multiple Risk Behaviors in Young People at Home, School, and Personal Levels

Updated

Abstract

A total of 70 eligible studies were included, primarily focusing on universal school-based interventions for preventing multiple risk behaviours among young people.

  • Universal school-based interventions may reduce the likelihood of tobacco use (odds ratio 0.77) and alcohol use (odds ratio 0.72) among participants.
  • Evidence suggests these interventions could be effective in lowering illicit drug use (odds ratio 0.74) and antisocial behaviour (odds ratio 0.81) at up to 12 months' follow-up.
  • Moderate-quality evidence indicates that such interventions may improve physical activity (odds ratio 1.32) among young people.
  • The evidence remains less certain for cannabis use, sexual risk behaviours, and unhealthy diet, with no strong benefits observed for family- or individual-level interventions.
  • Seven studies reported adverse effects, indicating that some interventions might increase risk behaviour among participants compared to controls.
  • Quality of evidence was generally moderate to low, highlighting the need for more robust studies in this area.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

RC is a scientific advisor for DECIPHer Impact, a not‐for‐profit company wholly owned by the Universities of Cardiff and Bristol, which licences, quality‐assures, and supports the delivery of evidence‐based public health promotion interventions. RC receives payment for this work. JW has been the recipient of research funding from the National Institute for Health Research (NIHR), UK, and the National Institute for Social Care and Health Research (NISCHR), Wales. DG has been the recipient of research funding from the NIHR, Ambulance Service and Medical Research Council (MRC), UK, and is a trustee for The Samaritans. MH has been the recipient of research funding from the MRC and Economic and Social Research Council, UK, and has received payment for unrelated activity from Gilead Sciences Inc, Bristol‐Myers Squibb, and Janssen, UK. GJM, DMC, JR, SHW, RK, CC, RL, VE, RL, and KEP ‐ no known interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free